G. J. Grover - Concepedia

Author

G. J. Grover

Also Known As

G GROVER, G Grover, G J Grover, G. Grover, G. J GROVER, G. J Grover, G. J. GROVER, G. J. Grover, G.J. Grover, Gary J. Grover

Publications

2.8K

Citations

H-Index

Concepts

All Affiliations

Bristol-Myers Squibb (United States)Bristol-Myers Squibb (Germany)Bristol-Myers Squibb (Sweden)

About

G. J. Grover is an author at Bristol-Myers Squibb (United States) specializing in cardiology, medicine, and physiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	13	521
2	Health Sciences	3	3	49
3	Natural Sciences	2	2	160
4	Allergy	2	2	35
5	Public Health	1	1	17

G. J. Grover

Publications

2.5K

Citations

H-Index

Page 1

	Year	Citations
Does Ischemic Preconditioning in the Human Involve Protein Kinase C and the ATP-Dependent K<sup>+</sup>Channel? M E Speechly-Dick, G. J. Grover, Derek M. Yellon Circulation Research	1995	291
Blockade of ischaemic preconditioning in dogs by the novel ATP dependent potassium channel antagonist sodium 5-hydroxydecanoate John A. Auchampach, G. J. Grover, G J Gross Cardiovascular Research	1992	275
Role of myocardial ATP-sensitive potassium channels in mediating preconditioning in the dog heart and their possible interaction with adenosine A1-receptors. G. J. Grover, Paul G. Sleph, Steven Dzwonczyk Circulation	1992	258
Anti-ischemic effects of the potassium channel activators pinacidil and cromakalim and the reversal of these effects with the potassium channel blocker glyburide. G. J. Grover, John R. McCullough, D E Henry, Journal of Pharmacology and Experimental Therapeutics	1989	177
The endothelin-1 receptor antagonist BQ-123 reduces infarct size in a canine model of coronary occlusion and reperfusion G. J. Grover, Steven Dzwonczyk, Charles S. Parham Cardiovascular Research	1993	151
Specific block of the anti-ischemic actions of cromakalim by sodium 5-hydroxydecanoate. John R. McCullough, Diane E. Normandin, Mary Lee Conder, Circulation Research HypertensionHeart FailurePharmacotherapyAtp-sensitive Potassium ChannelsMolecular Pharmacology	1991	138
Pharmacologic Characterization of BMS-191095, a Mitochondrial KATP Opener with No Peripheral Vasodilator or Cardiac Action Potential Shortening Activity G. J. Grover, A J D'Alonzo, Keith Garlid, Journal of Pharmacology and Experimental Therapeutics	2001	95
Cardioprotective effects of the potassium channel opener cromakalim: stereoselectivity and effects on myocardial adenine nucleotides. G. J. Grover, Jane W. Newburger, Paul G. Sleph, Journal of Pharmacology and Experimental Therapeutics	1991	90
Inhibition of nitric oxide synthesis does not affect ischemic preconditioning in isolated perfused rat hearts Edward O. Weselcouch, Anne J. Baird, Paul G. Sleph, American Journal of Physiology-Heart and Circulatory Physiology Ischemic PreconditioningCardiovascular PharmacologyEndothelium-derived Nitric OxideCardiovascular FunctionDiastolic Function	1995	79
Glyburide-reversible cardioprotective effect of BMS-180448 is independent of action potential shortening G. J. Grover, A J D'Alonzo, Paul G. Sleph, Cardiovascular Research	1995	74

Page 1